FDA Seeks Public Comment on Withdrawal of Pepaxto Accelerated Approval

The FDA is seeking public comment on its decision to withdraw accelerated approval for Oncopeptide’s Pepaxto (melphalan flufenamide), after a required postmarketing study showed that the drug plus dexamethasone failed to improve progression-free survival in patients with relapsed or refractory multiple myeloma.
Source: Drug Industry Daily